Coverage
News
Trial results, approvals, pricing changes, safety findings and market moves across peptides and GLP-1 medications — each traced to a primary source, each dated. For enforcement actions specifically, see the regulatory tracker.
- Trial results
- Approvals
- Pricing changes
- Safety findings
-
A menopause society has issued guidance on GLP-1 use, and it is candid about the evidence gap
Read more: A menopause society has issued guidance on GLP-1 use, and it is candid about the evidence gapThe Spanish Menopause Society published an expert position statement on 25 August covering the use of GLP-1 and dual incretin medications in peri- and postmenopausal women with overweight or obesity. It sets out 20 positions across body composition, cardiometabolic risk, musculoskeletal health, monitoring and interaction with hormone therapy. The most useful thing in it, for…
-
Semaglutide cut inflammation as well as weight in a review of nine trials
Read more: Semaglutide cut inflammation as well as weight in a review of nine trialsA systematic review and meta-analysis published on 29 August pooled nine randomised trials covering 6,239 adults with overweight or obesity but without diabetes, and found that injected semaglutide reduced a standard marker of inflammation by roughly 40% alongside the weight loss it is prescribed for. Serious adverse events were no more common than on placebo.…
-
Online-bought retatrutide, a hospital admission, and the limits of a single case
Read more: Online-bought retatrutide, a hospital admission, and the limits of a single caseA case report published on 26 August describes a man in his mid-30s with long-standing type 1 diabetes who was admitted to hospital with severe vomiting, diarrhoea, high blood sugar, ketones and acute kidney injury, shortly after self-administering a product he had bought online marketed as retatrutide. His partner took the same preparation and also…
-
Retatrutide met its endpoints in two more Phase 3 trials, but not on cardiovascular events
Read more: Retatrutide met its endpoints in two more Phase 3 trials, but not on cardiovascular eventsEli Lilly reported on 23 July 2026 that retatrutide, an investigational triple hormone receptor agonist, met its primary endpoint in two further Phase 3 trials. Participants with obesity and type 2 diabetes lost up to an average of 20.8% of body weight over 80 weeks; those with severe obesity and established cardiovascular disease lost up…
-
FDA approves Mounjaro to lower cardiovascular risk in type 2 diabetes
Read more: FDA approves Mounjaro to lower cardiovascular risk in type 2 diabetesThe FDA has approved a new indication for Mounjaro (tirzepatide): lowering the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack, or non-fatal stroke — in adults with type 2 diabetes who are at high risk for them. Eli Lilly announced the approval on 28 August 2026. It is the first cardiovascular…
-
Large cohort links GLP-1 drugs to more diabetic retinopathy, not to vision loss
Read more: Large cohort links GLP-1 drugs to more diabetic retinopathy, not to vision lossA large propensity-matched cohort study published in Diabetes, Obesity and Metabolism on 27 August 2026 found that people who started a GLP-1 receptor agonist were modestly more likely to be diagnosed with diabetic retinopathy, and more likely to undergo a retinopathy procedure, than matched people who started a DPP-4 inhibitor instead. The same study found…
-
Only 3 in 100 people on semaglutide hit the combined target in a 45,000-patient real-world study
Read more: Only 3 in 100 people on semaglutide hit the combined target in a 45,000-patient real-world studyTrial results describe what happens under close supervision with motivated volunteers. A study published in August in The Lancet Diabetes & Endocrinology asked a harder question: among 45,093 real patients with obesity and type 2 diabetes, how many actually hit a meaningful combined target a year after starting treatment? The answer for semaglutide was 3.0%.…
-
Lilly-authored analysis says Zepbound offsets other healthcare costs after 55
Read more: Lilly-authored analysis says Zepbound offsets other healthcare costs after 55Eli Lilly announced on 26 August 2026 that a real-world analysis of adults over 55 found lower healthcare costs among people who stayed on Zepbound (tirzepatide) than among matched untreated adults, and framed the result against the $195 monthly net price under Medicare’s GLP-1 Bridge programme. The underlying paper is peer-reviewed and published in Diabetes,…
-
A higher semaglutide dose reached 20.7% weight loss. It closes some of the gap to tirzepatide
Read more: A higher semaglutide dose reached 20.7% weight loss. It closes some of the gap to tirzepatideThe standard maintenance dose of Wegovy is 2.4 mg a week. STEP UP, a phase 3b randomised trial published in The Lancet Diabetes & Endocrinology, tested three times that — 7.2 mg — against both the standard dose and placebo over 72 weeks. Average weight loss was 20.7% on the high dose, 17.5% on 2.4…
-
Tirzepatide beat semaglutide head to head. The trial has two caveats worth knowing
Read more: Tirzepatide beat semaglutide head to head. The trial has two caveats worth knowingThe question people ask most often about these two drugs — which one works better — has a direct answer, and has had one since July 2025. In SURMOUNT-5, a trial that gave 751 adults either tirzepatide or semaglutide and followed them for 72 weeks, tirzepatide produced an average weight reduction of 20.2% against semaglutide’s…
-
Novo is cutting list prices by half. Cash payers will not notice
Read more: Novo is cutting list prices by half. Cash payers will not noticeNovo Nordisk announced in February that from 1 January 2027 it will cut the US list price of Wegovy, Ozempic and Rybelsus to $675 a month — a reduction of roughly 50% for Wegovy and 35% for Ozempic. It is a genuinely large number and it made a lot of headlines. For most people reading…